Literature DB >> 27998232

Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.

Alana Biggers1, Yushu Shi1, John Charlson1, Elizabeth C Smith1, Alicia J Smallwood1, Ann B Nattinger1, Purushottam W Laud1, Joan M Neuner1.   

Abstract

Purpose To investigate the role of out-of-pocket cost supports through the Medicare Part D Low-Income Subsidy on disparities in breast cancer hormonal therapy persistence and adherence by race or ethnicity. Methods A nationwide cohort of women age ≥ 65 years with a breast cancer operation between 2006 and 2007 and at least one prescription filled for oral breast cancer hormonal therapy was identified from all Medicare D enrollees. The association of race or ethnicity with nonpersistence (90 consecutive days with no claims for a hormonal therapy prescription) and nonadherence (medication possession rate < 80%) was examined. Survival analyses were used to account for potential differences in age, comorbidity, or intensity of other treatments. Results Among the 25,111 women in the study sample, 77% of the Hispanic and 70% of the black women received a subsidy compared with 21% of the white women. By 2 years, 69% of black and 70% of Hispanic patients were persistent compared with 61% of white patients. In adjusted analyses, patients in all three unsubsidized race or ethnicity groups had greater discontinuation than subsidized groups (white patients: hazard ratio [HR], 1.83; 95% CI, 1.70 to 1.95; black patients: HR, 2.09; 95% CI, 1.73 to 2.51; Hispanic patients: HR, 3.00; 95% CI, 2.37 to 3.89). Racial or ethnic persistence disparities that were present for unsubsidized patients were not present or reversed among subsidized patients. All three subsidized race or ethnicity groups also had higher adherence than all three unsubsidized groups, although with the smallest difference occurring in black women. Conclusion Receipt of a prescription subsidy was associated with substantially improved persistence to breast cancer hormonal therapy among white, black, and Hispanic women and lack of racial or ethnic disparities in persistence. Given high subsidy enrollment among black and Hispanic women, policies targeted at low-income patients have the potential to also substantially reduce racial and ethnic disparities.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27998232      PMCID: PMC5455308          DOI: 10.1200/JCO.2016.67.3350

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  33 in total

1.  Social capital and self-rated health: a contextual analysis.

Authors:  I Kawachi; B P Kennedy; R Glass
Journal:  Am J Public Health       Date:  1999-08       Impact factor: 9.308

2.  The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.

Authors:  Joan M Neuner; Sailaja Kamaraju; John A Charlson; Erica M Wozniak; Elizabeth C Smith; Alana Biggers; Alicia J Smallwood; Purushottam W Laud; Liliana E Pezzin
Journal:  J Natl Cancer Inst       Date:  2015-05-12       Impact factor: 13.506

3.  The differential impact of copayment on drug use in a Medicaid population.

Authors:  C E Reeder; A A Nelson
Journal:  Inquiry       Date:  1985       Impact factor: 1.730

4.  Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer.

Authors:  Christopher R Friese; T May Pini; Yun Li; Paul H Abrahamse; John J Graff; Ann S Hamilton; Reshma Jagsi; Nancy K Janz; Sarah T Hawley; Steven J Katz; Jennifer J Griggs
Journal:  Breast Cancer Res Treat       Date:  2013-03-31       Impact factor: 4.872

5.  Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.

Authors:  Dawn L Hershman; Jennifer Tsui; Jason D Wright; Ellie J Coromilas; Wei Yann Tsai; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2015-02-17       Impact factor: 44.544

6.  Adherence to tamoxifen over the five-year course.

Authors:  Timothy L Lash; Matthew P Fox; Jennifer L Westrup; Aliza K Fink; Rebecca A Silliman
Journal:  Breast Cancer Res Treat       Date:  2006-03-16       Impact factor: 4.872

7.  A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.

Authors:  Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag
Journal:  Ann Epidemiol       Date:  2007-05-25       Impact factor: 3.797

8.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

9.  HCFA's racial and ethnic data: current accuracy and recent improvements.

Authors:  S L Arday; D R Arday; S Monroe; J Zhang
Journal:  Health Care Financ Rev       Date:  2000

10.  Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer.

Authors:  Sumita S Bhatta; Ningqi Hou; Zakiya N Moton; Blase N Polite; Gini F Fleming; Olufunmilayo I Olopade; Dezheng Huo; Susan Hong
Journal:  Springerplus       Date:  2013-07-30
View more
  12 in total

1.  Patient and provider perspectives on delivery of oral cancer therapies.

Authors:  Caitlin C Murphy; Simon J Craddock Lee; David E Gerber; John V Cox; Hannah M Fullington; Robin T Higashi
Journal:  Patient Educ Couns       Date:  2019-06-20

2.  Breast cancer-specific survival by age: Worse outcomes for the oldest patients.

Authors:  Rachel A Freedman; Nancy L Keating; Nancy U Lin; Eric P Winer; Ines Vaz-Luis; Joyce Lii; Pedro Exman; William T Barry
Journal:  Cancer       Date:  2018-03-02       Impact factor: 6.860

Review 3.  The high price of anticancer drugs: origins, implications, barriers, solutions.

Authors:  Vinay Prasad; Kevin De Jesús; Sham Mailankody
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

4.  The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence.

Authors:  Joan M Neuner; Nicole M Fergestrom; Purushottam W Laud; Ann B Nattinger; Kirsten M M Beyer; Kathryn E Flynn; Liliana E Pezzin
Journal:  Cancer       Date:  2019-08-02       Impact factor: 6.860

5.  Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer.

Authors:  Alyce S Adams; Jeanne M Madden; Fang Zhang; Christine Y Lu; Dennis Ross-Degnan; Angelina Lee; Stephen B Soumerai; Dan Gilden; Neetu Chawla; Jennifer J Griggs
Journal:  Value Health       Date:  2017-07-06       Impact factor: 5.725

6.  Breast Cancer Health Disparities in Hispanics/Latinas.

Authors:  Silvia J Serrano-Gomez; Maria Carolina Sanabria-Salas; Laura Fejerman
Journal:  Curr Breast Cancer Rep       Date:  2020-05-28

7.  Cost sharing for breast cancer hormone therapy: How do dual eligible patients' copayment impact adherence.

Authors:  Siyu Ma; Donald S Shepard; Grant A Ritter; Robert E Martell; Cindy Parks Thomas
Journal:  PLoS One       Date:  2021-05-18       Impact factor: 3.240

8.  Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors.

Authors:  Rachel A Freedman; Anna C Revette; Dawn L Hershman; Kathryn Silva; Nora J Sporn; Joshua J Gagne; Elena M Kouri; Nancy L Keating
Journal:  Biores Open Access       Date:  2017-12-01

9.  Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.

Authors:  Bobby Daly; Olufunmilayo I Olopade; Ningqi Hou; Katharine Yao; David J Winchester; Dezheng Huo
Journal:  JAMA Oncol       Date:  2017-07-01       Impact factor: 31.777

10.  Octogenarians' Breast Cancer Is Associated with an Unfavorable Tumor Immune Microenvironment and Worse Disease-Free Survival.

Authors:  Maiko Okano; Masanori Oshi; Swagoto Mukhopadhyay; Qianya Qi; Li Yan; Itaru Endo; Toru Ohtake; Kazuaki Takabe
Journal:  Cancers (Basel)       Date:  2021-06-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.